|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 2/13/2025
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
Extended Efficacy SARS-COV-2 Vaccine
Application
A vaccine for SARS-COV-2 that can be used to protect against infection by future forms of Variant-of-Concern (VOC) or other SARS-like coronaviruses.
Key Benefits
An approach to developing a vaccine that would be effective against future mutations of SARS-COV-2.
A vaccine that elicits an immune response to conserved portions...
Published: 2/13/2025
Contributor(s): Chinglai Yang, Ling Ye, Samuel Stampfer, Rui Jin
|
|
Yongshi: A Wild Boar Peptide with Anti-Viral Activity Targeting COVID-19
Application
An antiviral cathelicidin peptide from wild boar that exhibits antiviral properties against SARS-CoV-2.
Key Benefits
Pan-coronavirus inhibitor that may be effective for all future variants.
Functions as an inhibitor of ongoing infection.
Early data suggests it is safe to use in human tissue.
Market Summary
Coronavirus disease...
Published: 2/13/2025
Contributor(s): Joshy Jacob, Mehul Suthar, Troy Von Beck, Nikita Mullick, Abigail Vanderheiden, Jeffrey Skolnick
|
|
Live Attenuated Zika Virus Vaccines
Application
Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines.
Key Benefits
Reduces neurotropism from Zika virus.
High safety and immunogenicity of chimeric vaccines.
Market Summary
Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 2/13/2025
Contributor(s): Baek Kim
|
|
Virus-Like Particles as RSV Vaccine Candidate
Application
Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection.
Key Benefits
Candidates may have the most effective anti-viral and anti-inflammatory response.
Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus.
Efficient, tunable and stable production...
Published: 2/13/2025
Contributor(s): Binh Ha, Larry Anderson, Elizabeth Wright
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 2/13/2025
Contributor(s): Rama Rao Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
|
Cross-Reactive Antibodies Against Influenza Virus
Application
Human recombinant antibodies against influenza, including H1N1, for the development of diagnostic tests and universal flu vaccines.
Key Benefits
Broadly protective antibodies against multiple influenza strains
Market Summary
Influenza spreads swiftly and globally, causing some of the most severe pandemics in the last century. Each year,...
Published: 2/13/2025
Contributor(s): Rafi Ahmed, Patrick Wilson, Jens Wrammert
|
